Recombinant Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1)

EAT; MCL1L; MCL1S; BCL2L3; TM; Myeloid Cell Leukemia Sequence 1, Bcl2 Related; Bcl-2-like protein 3; Bcl-2-related protein EAT/mcl1; mcl1/EAT

  • Product No.RPC615Hu01
  • Organism SpeciesHomo sapiens (Human) Same name, Different species.
  • SourceProkaryotic expression
  • HostE.coli
  • Endotoxin Level<1.0EU per 1µg (determined by the LAL method)
  • Subcellular LocationMembrane, Nucleus, Mitochondrion, Cytoplasm
  • Predicted Molecular Mass38.3kDa
  • Accurate Molecular Mass38kDa(Analysis of differences refer to the manual)
  • Residues & TagsArg6~Ile328 with N-terminal His Tag
  • Buffer FormulationPBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
  • Traits Freeze-dried powder
  • Purity> 80%
  • Isoelectric Point5.2
  • Applications Positive Control; Immunogen; SDS-PAGE; WB.
    If bio-activity of the protein is needed, please check active protein.
  • DownloadInstruction Manual
  • UOM 10µg50µg 200µg 1mg 5mg
  • FOB US$ 172  US$ 430  US$ 860  US$ 2580  US$ 6450 
    For more details, please contact local distributors!

SEQUENCE

USAGE

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

STORAGE

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

STABILITY

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Cancers Rationale for a Combination Therapy Consisting of MCL1-and MEK-Inhibitors in Acute Myeloid Leukemia Pubmed: 31718075
ACTA NEUROPATHOLOGICA COMMUNICATIONS Restoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastoma Pubmed: 32410663
Cancers (Basel) BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia. Cancers 2021, 13, 581 33540760